Department of Ophthalmology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Int Ophthalmol. 2023 Sep;43(9):3175-3184. doi: 10.1007/s10792-023-02717-y. Epub 2023 Apr 17.
To evaluate the effects of latanoprost, bimatoprost, and travoprost eye drops and their preservatives on each corneal layer thickness in patients with primary open-angle glaucoma (POAG).
We retrospectively analyzed 79 eyes of 79 patients with POAG who were receiving prostaglandin therapy. Patients were divided into three subgroups according to monotherapy with latanoprost, bimatoprost, and travoprost during a mean of 43.14 ± 19.12 months follow-up period. In addition, the central corneal epithelial thickness (CET), central corneal stromal thickness (CST), and total central corneal thickness (CCT) were measured by anterior segment optical coherence tomography (AS-OCT) at baseline and every six months after treatment initiation at each visit between 9 and 12 o'clock in the morning. Furthermore, intraocular pressure (IOP) was measured with Goldmann applanation tonometry (GAT) after AS-OCT measurements at each visit.
All three groups were not significantly different in age, gender, follow-up period, and mean intraocular pressure values (p > 0.05 for all). The reduction of CCT in the latanoprost, bimatoprost, and travoprost groups was 6.53 ± 3.17, 18.59 ± 8.42, and 10.1 ± 1.13 µm, respectively. The decrease in CST values was 4.65 ± 1.54, 15.84 ± 7.47, 9.69 ± 1.45 µm, and CET values were 1.88 ± 1.66, 2.75 ± 0.73, 0.41 ± 0.54 µm in all groups, respectively. A statistically significant thinning was observed in all corneal layers (p < 0.05) except the CST values in the latanoprost group and CET values in the travoprost group. However, no significant difference was found in the average reduction of CET, CST, and CCT values among the three groups (p > 0.05).
Topical treatment with latanoprost, bimatoprost, and travoprost affects each layer of the cornea separately according to the active and protective substances contained in these eye drops. On the other hand, the thinning effect on the corneal layers was similar in these three drugs because there was no significant difference between the three groups in the total amount of thinning of the corneal layers during the follow-up period.
评估拉坦前列素、比马前列素和曲伏前列素滴眼液及其防腐剂对原发性开角型青光眼（POAG）患者各角膜层厚度的影响。
我们回顾性分析了 79 例接受前列腺素治疗的 POAG 患者的 79 只眼。根据在平均 43.14±19.12 个月的随访期间接受拉坦前列素、比马前列素和曲伏前列素单药治疗的情况，将患者分为三组。此外，在上午 9 点至 12 点之间的每次就诊时，使用眼前节光学相干断层扫描（AS-OCT）测量中央角膜上皮厚度（CET）、中央角膜基质厚度（CST）和总中央角膜厚度（CCT）。每次就诊时，在 AS-OCT 测量后，还使用 Goldmann 压平眼压计（GAT）测量眼内压（IOP）。
所有三组在年龄、性别、随访时间和平均眼压值方面均无显著差异（p>0.05）。拉坦前列素、比马前列素和曲伏前列素组的 CCT 减少量分别为 6.53±3.17、18.59±8.42 和 10.1±1.13µm。CST 值降低分别为 4.65±1.54、15.84±7.47 和 9.69±1.45µm，CET 值分别为 1.88±1.66、2.75±0.73 和 0.41±0.54µm。所有组的所有角膜层均出现显著变薄（p<0.05），但拉坦前列素组的 CST 值和曲伏前列素组的 CET 值除外。然而，三组之间 CET、CST 和 CCT 值的平均减少量无显著差异（p>0.05）。
根据这些滴眼液中含有的活性和保护物质，局部使用拉坦前列素、比马前列素和曲伏前列素分别影响角膜的各个层。另一方面，由于在随访期间三组之间角膜各层总变薄量无显著差异，因此这三种药物对角膜层的变薄作用相似。
